Selpercatinib

Selpercatinib, sold under the brand name Retevmo, is a medication for the treatment of non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET or "rearranged during transfection").[3][1] It is taken by mouth.[1] The most common side effects include changes in laboratory tests (including increased liver enzymes, increased blood ... [wikipedia]